Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jan;31(1):122-131.
doi: 10.1111/hae.15146. Epub 2024 Dec 31.

Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype

Nuchanun Kessakorn  1   2 , Itsaraet Gosriwatana  3 , Nuttarak Sasipong  3 , Chonlatis Srichumpuang  1   2 , Chatphatai Moonla  4   5   6 , Darintr Sosothikul  1   2
Affiliations
Clinical Trial

Low-Dose Emicizumab Versus Low-/Intermediate-Dose Factor VIII Secondary Prophylaxis for Noninhibitor Haemophilia A Patients With Severe Bleeding Phenotype

Nuchanun Kessakorn et al. Haemophilia. 2025 Jan.

Abstract

Background: Subcutaneous emicizumab, a factor VIII (FVIII)-mimicking bispecific monoclonal antibody, can effectively prevent bleeds in haemophilia A (HA) patients with/without inhibitors; however, its standard-dose regimens are financially burdensome. Low-dose emicizumab prophylaxis may alternatively be applied to noninhibitor HA patients in resource-limited settings.

Methods: During 2023, Thai patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype (historical annualized bleeding rate [ABR] >5 bleeds/year before regular FVIII prophylaxis) who received low-/intermediate-dose FVIII secondary prophylaxis ≥8 months were enrolled. After the 4-day washout period, low-dose emicizumab prophylaxis (2.0-2.5 mg/kg every fortnight for two loading doses, then every 4 weeks) was implemented for 8 months. Pre-/post-emicizumab ABR, annualized joint bleeding rates (AJBR), haemophilia joint health scores (HJHS) and haemophilia-specific quality-of-life (QoL) scores were analysed. Emicizumab plasma levels on modified one-stage FVIII assays were also monitored.

Results: In 15 subjects, ABR (median of differences, -2 bleeds/year; interquartile range, -3 to 0; p = 0.002), but not AJBR (p = 0.07), were reduced after switching to low-dose emicizumab prophylaxis, although the pre-dose emicizumab plasma levels at the steady state, achieved since week 12, were modest (median monthly level, 8.4 µg/mL; interquartile range, 4.3-10.4). Concurrently, HJHS (p = 0.008) and QoL score (p < 0.001) were decreased, and 46.7% had zero bleeds while receiving low-dose emicizumab.

Conclusions: Low-dose emicizumab, compared to low-/intermediate-dose FVIII secondary prophylaxis, meaningfully improves bleeding prevention, joint health and QoL in patients with noninhibitor severe HA or moderate HA with severe bleeding phenotype. This regimen potentially helps address previously unmet needs in HA care among low-to-middle-income countries.

Trial registration: ClinicalTrials.gov identifier NCT06155955.

Keywords: emicizumab; factor VIII; haemophilia A.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. A. Srivastava, E. Santagostino, A. Dougall, et al., “WFH Guidelines for the Management of Hemophilia, 3rd Edition,” Haemophilia 26, suppl 6 (2020): 1–158.
    1. M. Shima, H. Hanabusa, M. Taki, et al., “Factor VIII‐Mimetic Function of Humanized Bispecific Antibody in Hemophilia A,” New England Journal of Medicine 374, no. 21 (2016): 2044–2053.
    1. M. U. Callaghan, C. Negrier, I. Paz‐Priel, et al., “Long‐Term Outcomes With Emicizumab Prophylaxis for Hemophilia A With or Without FVIII Inhibitors From the HAVEN 1–4 Studies,” Blood 137, no. 16 (2021): 2231–2242.
    1. J. Oldenburg, J. N. Mahlangu, B. Kim, et al., “Emicizumab Prophylaxis in Hemophilia A With Inhibitors,” New England Journal of Medicine 377, no. 9 (2017): 809–818.
    1. G. Young, R. Liesner, T. Chang, et al., “A Multicenter, Open‐Label Phase 3 Study of Emicizumab Prophylaxis in Children With Hemophilia A With Inhibitors,” Blood 134, no. 24 (2019): 2127–2138.

Publication types

MeSH terms

Associated data